ImmVira ' s MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

SHENZHEN, China, Jan. 18, 2022. ImmVira ' s breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials